<DOC>
	<DOCNO>NCT01468987</DOCNO>
	<brief_summary>The purpose study : - To compare blood sugar control LY2605541 insulin glargine 26 week treatment . - To compare number night time low blood sugar episode LY2605541 insulin glargine 26 week treatment . - To compare number participant LY2605541 reach blood sugar target without low blood sugar episode night take insulin glargine 26 week treatment . - To compare total number low blood sugar episode LY2605541 insulin glargine 26 week treatment .</brief_summary>
	<brief_title>A Study Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion Criteria Have Type 2 Diabetes Mellitus base World Health Organization ( WHO ) classification Had diabetes ≥1 year Have HbA1c value ≥7.0 % &lt; 12.0 % screen Have Body Mass Index ( BMI ) ≤45.0 kg/m^2 Participants glucose lower regimen contain least 1 daily insulin injection This inclusion criterion apply ONLY woman childbearing potential Are breastfeed Test negative pregnancy screen randomization Do intend become pregnant study Have practice reliable method birth control least 6 week prior screen Agree continue use reliable method birth control study , determine investigator ( 2 week follow last dose study drug ) Have access method communication site Have refrigeration home Capable , willing following : adhere multiple daily injection regimen , inject insulin cover vial syringe prefilled pen , attend appointment fast state , perform self blood glucose monitoring record keep require protocol , determine investigator . Caregiver may responsible Have give write informed consent participate study accordance local regulation Exclusion Criteria Continuous subcutaneous insulin infusion therapy prior screen Are use twice daily insulin glargine prior screen Excessive insulin resistance define receive daily dose insulin ≥ 2.0 units/kg time prerandomization Glucagonlike peptide1 ( GLP1 ) receptor agonist ( eg , exenatide , exenatide weekly , liraglutide ) , thiazolidinedione ( rosiglitazone , pioglitazone ) , pramlintide , use concurrently within 90 day prior screen Are use niacin preparation lipid lower medication and/or bile acid sequestrants within 90 day prior screen ; , use lipidlowering medication dose stable ≥90 day prior screen Have fast hypertriglyceridemia ( define &gt; 4.5 mmol/L , &gt; 400 mg/dL ) screening Are currently take , take within 90 day precede screening , prescription overthecounter medication weight loss Have episode severe hypoglycemia ( define require assistance due neurologically disable hypoglycemia ) within 6 month prior entry study Have 2 emergency room visit hospitalization due poor glucose control within 6 month prior screen Have 1 episode ketoacidosis hyperosmolar state/coma require hospitalization within 6 month prior screen Have cardiac disease functional status New York Heart Association Class III IV ( per New York Heart Association Cardiac Disease Classification ) Are currently receive renal dialysis serum creatinine ≥2.0 mg/dL , except participant take metformin require follow local labeling restriction regard metformin use serum creatinine Have obvious clinical sign symptom liver disease ( exclude nonalcoholic fatty liver disease [ NAFLD ] , acute chronic hepatitis , non alcoholic steatohepatitis [ NASH ] , elevate liver enzyme measurement indicate : total bilirubin ≥2X upper limit normal ( ULN ) define central laboratory , alanine aminotransferase ( ALT ) /serum glutamic pyruvic transaminase ( SGPT ) &gt; 2.5X ULN define central laboratory , aspartate aminotransferase ( AST ) /serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 2.5X ULN define central laboratory Have active untreated malignancy , remission clinically significant malignancy ( basal cell squamous cell skin cancer ) less 5 year , increase risk develop cancer recurrence cancer opinion investigator Have know develop hypersensitivity allergy study insulins excipients Have blood transfusion severe blood loss within 3 month prior screen know hemoglobinopathy , hemolytic anemia , sickle cell anemia , traits hemoglobin abnormality know interfere HbA1c measurement Receiving chronic ( lasting longer 14 consecutive day ) systemic glucocorticoid therapy ( exclude topical , intraocular , intranasal , inhaled preparation ) receive therapy within 8 week immediately screen exception replacement therapy adrenal insufficiency Diagnosed clinically significant diabetic autonomic neuropathy , opinion investigator Have organ transplant Have condition ( include know drug alcohol abuse psychiatric disorder include eat disorder ) preclude participant follow completing protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>